Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
Abstract Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such ca...
Main Authors: | Xuping Wu, Qi Wang, Yousheng Lu, Jinye Zhang, Hanwei Yin, Yongxiang Yi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-03-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-85688-3 |
Similar Items
-
Hepatocyte Hyperproliferation upon Liver-Specific Co-disruption of Thioredoxin-1, Thioredoxin Reductase-1, and Glutathione Reductase
by: Justin R. Prigge, et al.
Published: (2017-06-01) -
High-fat diet-induced changes in liver thioredoxin and thioredoxin reductase as a novel feature of insulin resistance
by: Huijun Qin, et al.
Published: (2014-01-01) -
Biomarkers of Adverse Response to Mercury: Histopathology versus Thioredoxin Reductase Activity
by: Vasco Branco, et al.
Published: (2012-01-01) -
Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity
by: Xiaoqing Zheng, et al.
Published: (2018-04-01) -
Therapeutic Effects of an Inhibitor of Thioredoxin Reductase on Liver Fibrosis by Inhibiting the Transforming Growth Factor-β1/Smads Pathway
by: Wenxuan Jiao, et al.
Published: (2021-09-01)